
NASDAQHealthcareBiotechnology
أحدث البيانات المتاحة
254.19 US$
+12.73 US$ · +5.27%
Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts target a broad spectrum of medical needs, including infectious diseases, cancer immunology, rare conditions, cardiovascular ailments, and autoimmune disorders, with operations spanning the United States, Europe, and other global markets. The company's diverse product pipeline encompasses various vaccine candidates: those for respiratory illnesses like COVID-19, influenza, and respiratory syncytial virus (RSV); latent viral infections such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), herpes simplex virus (HSV), and varicella-zoster virus (VZV); and public health threats like Zika and Nipah. Additionally, Moderna is advancing systemic secreted and cell surface-targeted therapeutics, an array of cancer vaccines (including personalized, KRAS, and checkpoint varieties), intratumoral immuno-oncology products, localized regenerative treatments, systemic intracellular medicines, and inhaled pulmonary solutions. Moderna maintains strategic alliances with several prominent entities, including AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, Carisma Therapeutics, Inc., Metagenomi, Inc., the Defense Advanced Research Projects Agency (DARPA), the Biomedical Advanced Research and Development Authority (BARDA), the Institute for Life Changing Medicines, and The Bill & Melinda Gates Foundation. It also holds a collaboration and license agreement with Chiesi Farmaceutici S.P.A. Founded in 2010 as Moderna Therapeutics, Inc., the company officially became Moderna, Inc. in August 2018. Its corporate headquarters are located in Cambridge, Massachusetts.
أحدث البيانات المتاحة
254.19 US$
+12.73 US$ · +5.27%
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts target a broad spectrum of medical needs, including infectious diseases, cancer immunology, rare conditions, cardiovascular ailments, and autoimmune disorders, with operations spanning the United States, Europe, and other global markets. The company's diverse product pipeline encompasses various vaccine candidates: those for respiratory illnesses like COVID-19, influenza, and respiratory syncytial virus (RSV); latent viral infections such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), herpes simplex virus (HSV), and varicella-zoster virus (VZV); and public health threats like Zika and Nipah. Additionally, Moderna is advancing systemic secreted and cell surface-targeted therapeutics, an array of cancer vaccines (including personalized, KRAS, and checkpoint varieties), intratumoral immuno-oncology products, localized regenerative treatments, systemic intracellular medicines, and inhaled pulmonary solutions. Moderna maintains strategic alliances with several prominent entities, including AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, Carisma Therapeutics, Inc., Metagenomi, Inc., the Defense Advanced Research Projects Agency (DARPA), the Biomedical Advanced Research and Development Authority (BARDA), the Institute for Life Changing Medicines, and The Bill & Melinda Gates Foundation. It also holds a collaboration and license agreement with Chiesi Farmaceutici S.P.A. Founded in 2010 as Moderna Therapeutics, Inc., the company officially became Moderna, Inc. in August 2018. Its corporate headquarters are located in Cambridge, Massachusetts.
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
نقاط GoAI
احتفاظ
تقييم
24
مرتفع السعر
المشاعر
50
مختلط
المخاطر
46
مخاطر أعلى من المعتاد
الزخم
82
صعود قوي
بحث كامل عن GoAI
تابع للاطلاع على أدلة ومحفزات ومخاطر أعمق.
Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts target a broad spectrum of medical needs, including infectious diseases, cancer immunology, rare conditions, cardiovascular ailments, and autoimmune disorders, with operations spanning the United States, Europe, and other global markets. The company's diverse product pipeline encompasses various vaccine candidates: those for respiratory illnesses like COVID-19, influenza, and respiratory syncytial virus (RSV); latent viral infections such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), herpes simplex virus (HSV), and varicella-zoster virus (VZV); and public health threats like Zika and Nipah. Additionally, Moderna is advancing systemic secreted and cell surface-targeted therapeutics, an array of cancer vaccines (including personalized, KRAS, and checkpoint varieties), intratumoral immuno-oncology products, localized regenerative treatments, systemic intracellular medicines, and inhaled pulmonary solutions. Moderna maintains strategic alliances with several prominent entities, including AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, Carisma Therapeutics, Inc., Metagenomi, Inc., the Defense Advanced Research Projects Agency (DARPA), the Biomedical Advanced Research and Development Authority (BARDA), the Institute for Life Changing Medicines, and The Bill & Melinda Gates Foundation. It also holds a collaboration and license agreement with Chiesi Farmaceutici S.P.A. Founded in 2010 as Moderna Therapeutics, Inc., the company officially became Moderna, Inc. in August 2018. Its corporate headquarters are located in Cambridge, Massachusetts.
الربحية كنسبة مئوية من الإيرادات المعلنة.
الإيرادات
الدخل التشغيلي
صافي الدخل
| البند (USD) | السنة المالية 2025 | السنة المالية 2024 | السنة المالية 2023 | السنة المالية 2022 | السنة المالية 2021 |
|---|---|---|---|---|---|
| الإيرادات | 1.94 مليار USD | 3.2 مليار USD | 6.85 مليار USD | 18.88 مليار USD | 17.74 مليار USD |
| تكلفة البضاعة المباعة | 868 مليون USD | 1.46 مليار USD | 4.69 مليار USD | 5.42 مليار USD | 2.62 مليار USD |
| الربح الإجمالي | 1.08 مليار USD | 1.74 مليار USD | 2.16 مليار USD | 13.46 مليار USD | 15.12 مليار USD |
| البحث والتطوير | 3.13 مليار USD | 4.54 مليار USD | 4.85 مليار USD | 3.3 مليار USD | 1.99 مليار USD |
| مصاريف البيع والمصاريف العمومية والإدارية | 1.02 مليار USD | 1.17 مليار USD | 1.55 مليار USD | 1.13 مليار USD | 567 مليون USD |
| نفقات التشغيل | 4.15 مليار USD | 5.68 مليار USD | 6.39 مليار USD | 4.04 مليار USD | 1.82 مليار USD |
| دخل الفوائد | 314 مليون USD | 425 مليون USD | 421 مليون USD | 200 مليون USD | 18 مليون USD |
| مصاريف الفوائد | 10 مليون USD | 24 مليون USD | 38 مليون USD | 29 مليون USD | 18 مليون USD |
| الاستهلاك والإطفاء | 215 مليون USD | 189 مليون USD | 621 مليون USD | 348 مليون USD | 232 مليون USD |
| الدخل التشغيلي | −3.07 مليار USD | −3.95 مليار USD | −4.24 مليار USD | 9.42 مليار USD | 13.3 مليار USD |
| صافي الدخل | −2.82 مليار USD | −3.56 مليار USD | −4.71 مليار USD | 8.36 مليار USD | 12.2 مليار USD |
تم تحديث حقائق الشركة 9 نوفمبر 2026.
قد تتغير تقديرات المحللين الخارجيين، وهي ليست توصيات من GoAI.
صناديق متداولة تفصح عن تعرضها لهذا السهم.
State Street SPDR S&P 500 ETF1557.T173.66 مليار0.14%123.21 ترليون JPY0.09%117,200 JP¥+1.17%
Vanguard Morningstar Total Stock Market ETFVTI2.2 مليار0.09%689.2 مليار USD0.03%361.93 US$+0.39%
Invesco QQQ Trust, Series 1QQQ2.02 مليار0.46%446.09 مليار USD0.18%656.1 US$+1.40%
Vanguard S&P 500 ETFVOO1.88 مليار0.11%1 ترليون USD0.03%675.99 US$+0.30%
iShares Core S&P 500 ETFIVV1.27 مليار0.15%852.94 مليار USD0.03%738.68 US$+0.34%
State Street SPDR S&P 500 ETFSPY1.1 مليار0.14%777.75 مليار USD0.09%735.29 US$+0.31%
Vanguard Morningstar Small-Cap ETFVB778.7 مليون0.44%76.9 مليار USD0.03%285.64 US$+0.59%
Vanguard Morningstar Mid-Cap ETFVO740.83 مليون0.34%103.4 مليار USD0.03%79.38 US$-0.14%
State Street SPDR S&P 500 ETF1557.T
Vanguard Morningstar Total Stock Market ETFVTI
Invesco QQQ Trust, Series 1QQQ
Vanguard S&P 500 ETFVOO
iShares Core S&P 500 ETFIVV
State Street SPDR S&P 500 ETFSPY
Vanguard Morningstar Small-Cap ETFVB
Vanguard Morningstar Mid-Cap ETFVOالمحتوى المُنشأ بالذكاء الاصطناعي وبيانات السوق المتأخرة لأغراض معلوماتية وتعليمية فقط، ولا تُعد نصيحة استثمارية.